Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities

被引:22
|
作者
Meyers, Kathrine [1 ]
Golub, Sarit A. [2 ]
机构
[1] Aaron Diamond AIDS Res Ctr, New York, NY USA
[2] CUNY Hunter Coll, New York, NY 10065 USA
关键词
HIV prevention; implementation; long-acting antiretrovirals; preexposure prophylaxis; sociobehavioral research; PREEXPOSURE PROPHYLAXIS PREP; UNINTENDED PREGNANCY; ATTITUDES; RISK; TRIALS; PERCEPTION; ADHERENCE; KNOWLEDGE; SEX;
D O I
10.1097/COH.0000000000000159
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewBroad-based access, uptake, and dissemination of daily oral HIV preexposure prophylaxis (PrEP) have been slow, despite strong evidence for efficacy. Effective and efficient implementation of long-acting HIV prevention products will require both analysis of the dynamics and determinants of daily oral PrEP implementation and identification of the distinct challenges and opportunities inherent in emerging technologies.Recent findingsEvidence suggests the importance of addressing implementation issues at three levels: patient, provider, and system. Patient-level factors include targeted education and messaging, tailored supports to enhance acceptability and uptake, and effective strategies for promoting adherence/persistence and retention in care. Provider-level factors include engaging a broad mix of providers, while ensuring adequate training and support for patient assessment, counseling, and follow-up. Systems-level factors include optimal delivery modalities, resource allocation, and ensuring access to populations most in need of new prevention options.SummaryFormative social/behavioral research must be undertaken proactively to prepare for and address future implementation challenges and reduce the gap between proving efficacy in clinical trials and assuring real-world effectiveness. Conceptualizing new HIV prevention technologies as behavioral interventions at the level of the patient, provider, and system will be paramount to effective and efficient implementation.
引用
收藏
页码:290 / 295
页数:6
相关论文
共 50 条
  • [1] Long-acting rilpivirine for HIV prevention
    Jackson, Akil
    McGowan, Ian
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 253 - 257
  • [2] Implementation challenges for long-acting antivirals as treatment
    Havlir, Diane
    Gandhi, Monica
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 282 - 289
  • [3] Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection
    Arya, Vikram
    Au, Stanley
    Belew, Yodit
    Miele, Peter
    Struble, Kimberly
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 278 - 281
  • [4] Long-acting agents for HIV treatment and prevention
    Linda-Gail Bekker
    Nature Medicine, 2022, 28 : 1542 - 1543
  • [5] In PrEP: Long-acting antivirals for HIV prevention
    Sharma, Amit
    CELL HOST & MICROBE, 2022, 30 (02) : 148 - 150
  • [6] Long-acting agents for HIV treatment and prevention
    Bekker, Linda-Gail
    NATURE MEDICINE, 2022, 28 (08) : 1542 - 1543
  • [7] Long-Acting HIV Drugs for Treatment and Prevention
    Gulick, Roy M.
    Flexner, Charles
    ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 137 - 150
  • [8] Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
    Haddad, Peter M.
    Correll, Christoph U.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (04) : 473 - 493
  • [9] Long-acting injection therapies: New opportunities and challenges
    Lee M.
    MMW - Fortschritte der Medizin, 2024, 166 (Suppl 2) : 32 - 34
  • [10] Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations
    Mgodi, Nyaradzo M.
    Murewanhema, Grant
    Moyo, Enos
    Samba, Chesterfield
    Musuka, Godfrey
    Dzinamarira, Tafadzwa
    Brown, Joelle M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26